Literature DB >> 24574519

NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.

Varvara K Kozyreva1, Sarah L McLaughlin, Ryan H Livengood, Robin A Calkins, Laura C Kelley, Anuradha Rajulapati, Ryan J Ice, Matthew B Smolkin, Scott A Weed, Elena N Pugacheva.   

Abstract

UNLABELLED: The prometastatic protein NEDD9 (neural precursor cell expressed, developmentally downregulated 9) is highly expressed in many cancers and is required for mesenchymal individual cell migration and progression to the invasive stage. Nevertheless, the molecular mechanisms of NEDD9-driven migration and the downstream targets effecting metastasis are not well defined. In the current study, knockdown of NEDD9 in highly metastatic tumor cells drastically reduces their migratory capacity due to disruption of actin dynamics at the leading edge. Specifically, NEDD9 deficiency leads to a decrease in the persistence and stability of lamellipodial protrusions similar to knockdown of cortactin (CTTN). Mechanistically, it was shown that NEDD9 binds to and regulates acetylation of CTTN in an Aurora A kinase (AURKA)/HDAC6-dependent manner. The knockdown of NEDD9 or AURKA results in an increase in the amount of acetylated CTTN and a decrease in the binding of CTTN to F-actin. Overexpression of the deacetylation mimicking (9KR) mutant of CTTN is sufficient to restore actin dynamics at the leading edge and migration proficiency of the tumor cells. Inhibition of AURKA and HDAC6 activity by alisertib and Tubastatin A in xenograft models of breast cancer leads to a decrease in the number of pulmonary metastases. Collectively, these findings identify CTTN as the key downstream component of NEDD9-driven migration and metastatic phenotypes. IMPLICATIONS: This study provides a mechanistic platform for therapeutic interventions based on AURKA and HDAC6 inhibition for patients with metastatic breast cancer to prevent and/or eradicate metastases. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24574519      PMCID: PMC4020952          DOI: 10.1158/1541-7786.MCR-13-0654

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors.

Authors:  V W Wang; D A Bell; R S Berkowitz; S C Mok
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  HDAC6 is required for invadopodia activity and invasion by breast tumor cells.

Authors:  Mercedes Rey; Marie Irondelle; François Waharte; Floria Lizarraga; Philippe Chavrier
Journal:  Eur J Cell Biol       Date:  2010-10-23       Impact factor: 4.492

3.  Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Authors:  Sridurga Mithraprabhu; Tiffany Khong; Simon S Jones; Andrew Spencer
Journal:  Br J Haematol       Date:  2013-05-21       Impact factor: 6.998

4.  Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation.

Authors:  A M Weaver; A V Karginov; A W Kinley; S A Weed; Y Li; J T Parsons; J A Cooper
Journal:  Curr Biol       Date:  2001-03-06       Impact factor: 10.834

5.  Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines.

Authors:  D H Campbell; A deFazio; R L Sutherland; R J Daly
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

6.  Src binds cortactin through an SH2 domain cystine-mediated linkage.

Authors:  Jason V Evans; Amanda G Ammer; John E Jett; Chris A Bolcato; Jason C Breaux; Karen H Martin; Mark V Culp; Peter M Gannett; Scott A Weed
Journal:  J Cell Sci       Date:  2012-10-24       Impact factor: 5.285

7.  Cortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence.

Authors:  Laura C Kelley; Karen E Hayes; Amanda Gatesman Ammer; Karen H Martin; Scott A Weed
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

Review 8.  Cortactin branches out: roles in regulating protrusive actin dynamics.

Authors:  Amanda Gatesman Ammer; Scott A Weed
Journal:  Cell Motil Cytoskeleton       Date:  2008-09

9.  Lung metastasis genes couple breast tumor size and metastatic spread.

Authors:  Andy J Minn; Gaorav P Gupta; David Padua; Paula Bos; Don X Nguyen; Dimitry Nuyten; Bas Kreike; Yi Zhang; Yixin Wang; Hemant Ishwaran; John A Foekens; Marc van de Vijver; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-09       Impact factor: 11.205

10.  NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 3D cell migration.

Authors:  Jessie Zhong; Jaime B Baquiran; Navid Bonakdar; Justin Lees; Yu Wooi Ching; Elena Pugacheva; Ben Fabry; Geraldine M O'Neill
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

View more
  14 in total

1.  Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.

Authors:  Varvara K Kozyreva; Anna A Kiseleva; Ryan J Ice; Brandon C Jones; Yuriy V Loskutov; Fatimah Matalkah; Matthew B Smolkin; Kristina Marinak; Ryan H Livengood; Mohamad A Salkeni; Sijin Wen; Hannah W Hazard; Ginger P Layne; Callee M Walsh; Pamela S Cantrell; Greg W Kilby; Sricharan Mahavadi; Neal Shah; Elena N Pugacheva
Journal:  Mol Cancer Ther       Date:  2016-05-27       Impact factor: 6.261

2.  Dual Targeting of Mesenchymal and Amoeboid Motility Hinders Metastatic Behavior.

Authors:  Brandon C Jones; Laura C Kelley; Yuriy V Loskutov; Kristina M Marinak; Varvara K Kozyreva; Matthew B Smolkin; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2017-02-24       Impact factor: 5.852

3.  Critical review of non-histone human substrates of metal-dependent lysine deacetylases.

Authors:  Tasha B Toro; Terry J Watt
Journal:  FASEB J       Date:  2020-08-30       Impact factor: 5.191

Review 4.  CAS proteins in health and disease: an update.

Authors:  Anna S Nikonova; Anna V Gaponova; Alexander E Kudinov; Erica A Golemis
Journal:  IUBMB Life       Date:  2014-06-24       Impact factor: 3.885

5.  The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.

Authors:  Phuong-Hien Nguyen; Tamina Seeger-Nukpezah; Lisa Rusyn; Sebastian Reinartz; Anastasia Nikiforov; Nelly Mikhael; Alexander Vom Stein; Viktoria Kohlhas; Johannes Bloehdorn; Stephan Stilgenbauer; Philipp Lohneis; Reinhard Buettner; Sandra Robrecht; Kirsten Fischer; Christian Pallasch; Michael Hallek
Journal:  Leukemia       Date:  2022-05-06       Impact factor: 12.883

Review 6.  Modulation of cellular processes by histone and non-histone protein acetylation.

Authors:  Maria Shvedunova; Asifa Akhtar
Journal:  Nat Rev Mol Cell Biol       Date:  2022-01-18       Impact factor: 113.915

7.  Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.

Authors:  Yong-Hui Ding; Zhi-Wei Zhou; Chun-Fang Ha; Xue-Yu Zhang; Shu-Ting Pan; Zhi-Xu He; Jeffrey L Edelman; Dong Wang; Yin-Xue Yang; Xueji Zhang; Wei Duan; Tianxin Yang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-01-09       Impact factor: 4.162

8.  HDAC6 deacetylase activity is critical for lipopolysaccharide-induced activation of macrophages.

Authors:  Bing Yan; Songbo Xie; Zhu Liu; Jie Ran; Yuanyuan Li; Jian Wang; Yang Yang; Jun Zhou; Dengwen Li; Min Liu
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

Review 9.  Cas proteins: dodgy scaffolding in breast cancer.

Authors:  Giusy Tornillo; Paola Defilippi; Sara Cabodi
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

Review 10.  Emerging roles of histone modifications and HDACs in RNA splicing.

Authors:  Raneen Rahhal; Edward Seto
Journal:  Nucleic Acids Res       Date:  2019-06-04       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.